Abstract | OBJECTIVE: METHODS: This was an open-label study involving 78 patients with multiple sclerosis treated with Betaferon 8 million IU (MIU) subcutaneously (SC) every other day (n = 20), Rebif 22 micro g SC 3 times weekly (n = 25), or Avonex 30 micro g IM once weekly (n = 33). Every 3 months, blood samples were collected and sera were analyzed for NAbs using an antiviral cytopathic effect assay. Patients were categorized according to their NAb status: NAb negative (NAb-); isolated NAb positive (NAb+), patients with > or =1 positive sample (titer > or = 20); and persistent NAb+, patients with > or =2 consecutive positive samples (titer > or = 20). Patients who were NAb- and persistent NAb+ were compared for relapse rate, time between first and second relapse, percentage of relapse-free patients, and percentage of patients who had a sustained progression of > or =1 point on the Expanded Disability Status Scale (EDSS). RESULTS: The incidence of persistent NAb+ patients was 35% for Betaferon, 20% for Rebif, and 3% for Avonex. During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. In addition, the mean relapse rate was higher (p = 0.039), mean time between first and second relapse was shorter (13 vs 21 months; p = 0.0064), and there was a trend suggesting that NAbs affected the probability of remaining relapse free (p = 0.08). A higher percentage of NAb+ patients versus NAb- patients had worsening of EDSS scores during follow-up (p = 0.013). CONCLUSION: Persistent NAbs significantly reduce the clinical efficacy of IFNbeta.
|
Authors | S Malucchi, A Sala, F Gilli, R Bottero, A Di Sapio, M Capobianco, A Bertolotto |
Journal | Neurology
(Neurology)
Vol. 62
Issue 11
Pg. 2031-7
(Jun 08 2004)
ISSN: 1526-632X [Electronic] United States |
PMID | 15184610
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Isoantibodies
- Interferon beta-1b
- Interferon-beta
- Interferon beta-1a
|
Topics |
- Adolescent
- Adult
- Aged
- Antibody Specificity
- Antiviral Agents
(immunology, pharmacology)
- Cell Line, Tumor
- Cytopathogenic Effect, Viral
(drug effects)
- Disease Progression
- Disease-Free Survival
- Drug Resistance
- Encephalomyocarditis virus
(drug effects, physiology)
- Female
- Follow-Up Studies
- Humans
- Incidence
- Interferon beta-1a
- Interferon beta-1b
- Interferon-beta
(antagonists & inhibitors, immunology, pharmacology, therapeutic use)
- Isoantibodies
(immunology)
- Life Tables
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, immunology)
- Neutralization Tests
- Prospective Studies
- Severity of Illness Index
- Treatment Outcome
|